<DOC>
	<DOCNO>NCT00707083</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy work different way stop growth cancer cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill cancer cell . It yet know combination chemotherapy regimen effective treat acute lymphoblastic leukemia . PURPOSE : This randomized clinical trial study side effect two combination chemotherapy regimens see well work treat child newly diagnose acute lymphoblastic leukemia .</brief_summary>
	<brief_title>Two Combination Chemotherapy Regimens Treating Children With Newly Diagnosed Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare incidence marrow suppression 2 method maintenance treatment child acute lymphoblastic leukemia . - Compare incidence liver toxicity 2 method maintenance treatment patient . Secondary - Determine difference infection rate related hospitalization patient . OUTLINE : This multicenter study . Patients stratify accord risk ( high v intermediate v standard ) , age year ( 0 5 v 6 9 v 10 17 ) , sex . - Patients standard-risk disease : - Induction therapy : Patients receive prednisolone IV orally three time daily day 1-7 ; oral dexamethasone three time daily day 8-28 ; asparaginase IV 1 hour intramuscularly day 8 , 11 , 14 , 17 , 20 , 23 , 26 , 29 ; vincristine IV day 8 , 15 , 22 , 29 ; daunorubicin hydrochloride IV 1 hour day 8 15 ; methotrexate intrathecally ( IT ) day 1 , 15 , 33 . - Early intensification ( EI ) therapy : Patients receive cyclophosphamide IV 1 hour day 36 , cytarabine IV continuously day 38-41 45-48 , oral mercaptopurine daily day 36-50 , methotrexate IT day 38 45 . - Consolidation therapy : Two week complete EI therapy , patient receive oral mercaptopurine daily day 1-56 methotrexate IV 24 hour IT day 8 , 22 , 36 , 50 . - Delayed intensification ( DI ) therapy : - DI/a : Patients receive dexamethasone orally IV three time daily day 1-7 15-21 , doxorubicin hydrochloride IV 1 hour day 1 , 8 , 15 ; vincristine IV day 1 , 8 , 15 ; asparaginase subcutaneously ( SC ) IV 1 hour day 1 , 4 , 8 , 11 . - DI/b : Patients receive cyclophosphamide IV 1 hour day 29 , cytarabine IV continuously day 31-34 38-41 , oral thioguanine daily day 29-42 , methotrexate IT day 31 38 . - Maintenance therapy : Patients randomize one two treatment arm . Patients consent randomization receive conventional therapy ( arm I ) . - Arm I ( conventional ) : Patients receive oral mercaptopurine oral methotrexate day 1-56 , dexamethasone IV day 1-5 29-33 , vincristine IV day 1 29 , methotrexate IT day 50 . Treatment repeat every 8 week 8 course girls 11 course boy . - Arm II ( intervention ) : Patients receive oral mercaptopurine daily day 8-28 36-56 ; oral methotrexate day 8,15 , 22 , 36 , 43 , 50 ; dexamethasone IV day 1-5 29-33 ; vincristine IV day 1 29 . Patients also receive methotrexate IT day 1 , every 8 week , 8 course . - Patients intermediate-risk disease : - Induction therapy : Patients receive prednisolone , dexamethasone , asparaginase standard-risk induction therapy . Patients also receive vincristine IV daunorubicin hydrochloride IV 1 hour day 8 , 15 , 22 , 29 ; methotrexate IT day 1 ; triple intrathecal therapy ( TIT ; high-dose methotrexate , cytarabine , hydrocortisone sodium succinate ) day 15 33 . - First EI therapy : Patients receive cyclophosphamide , cytarabine , mercaptopurine standard-risk EI . Patients also receive TIT day 38 . - Second EI therapy : Beginning 2 week complete first EI , patient receive cyclophosphamide 1 hour day 1 , oral mercaptopurine day 1-14 , cytarabine IV day 3-6 10-13 , TIT day 3 . - Consolidation therapy : Beginning 2 week complete second EI , patient receive mercaptopurine standard-risk consolidation therapy . Patients also receive methotrexate IV 24 hour TIT day 8 , 22 , 36 , 50 . - First DI therapy : Patients receive treatment standard-risk DI . - Interim maintenance therapy : Patients receive oral mercaptopurine oral methotrexate day 1-56 . - Second DI therapy : Patients receive DI/a D1/b ( without methotrexate ) standard-risk DI . Patients also receive TIT day 31 38 . - Maintenance therapy : Patients randomize 1 2 treatment arm : - Arm I ( conventional ) : Patients receive mercaptopurine , methotrexate , dexamethasone , vincristine standard-risk maintenance therapy arm I . Patients also receive TIT day 50 . Treatment repeat every 8 week 8 course girls 11 course boy . - Arm II ( intervention ) : Patients receive treatment standard-risk maintenance therapy arm II . - Patients high-risk disease : - Induction therapy : Patients receive treatment intermediate-risk induction therapy . - First EI therapy : Patients receive treatment intermediate-risk first EI . - Second EI therapy : Patients receive treatment intermediate-risk second EI . - Consolidation therapy ( interval block 2 week ) : - Block 1 : Patients receive dexamethasone orally IV three time daily day 1-5 , vincristine IV day 1 6 , high-dose methotrexate IV 24 hour day 1 , cyclophosphamide IV 1 hour twice daily day 2-4 , cytarabine IV 3 hour twice day 5 , asparaginase IV 2 hour day 6 11 , TIT day 1 . - Block 2 : Patients receive dexamethasone , high-dose methotrexate , asparaginase , TIT block 1 . Patients also receive vindesine IV twice daily day 1 6 , ifosfamide IV 1 hour twice daily day 2-4 , daunorubicin hydrochloride IV 24 hour day 5 . - Block 3 : Patients receive dexamethasone asparaginase block 1 . Patients also receive high-dose cytarabine IV 3 hour twice daily day 1 2 , etoposide IV 1 hour five time day 3-5 , TIT day 5 . - Blocks 1-3 repeat . Patients proceed delay intensification therapy . - Delayed intensification therapy : Patients receive dexamethasone orally IV three time daily day 1-7 15-21 ; doxorubicin hydrochloride IV vincristine IV day 8 , 15 , 22 , 29 ; asparaginase IV day 8 , 11 , 15 , 18 . Patients also receive cyclophosphamide IV day 36 , cytarabine IV day 38-41 45-48 , thioguanine IV day 36-49 , TIT day 38 45 . - Maintenance therapy : Patients receive oral mercaptopurine oral methotrexate daily day 1-14 , cyclophosphamide 1 hour cytarabine 1 hour day 15-21 , oral dexamethasone two three time daily 5 day day 29-35 , vincristine IV day 29 , TIT day 22 . Treatment repeat every 4 week . After 10 course , patient longer receive TIT . After 12 course , patient longer receive cyclophosphamide cytarabine . At time patient continue mercaptopurine methotrexate day 1-21 . After 20 course , patient longer receive dexamethasone vincristine . At time , patient continue mercaptopurine methotrexate day 1-28 . Females receive 17 course male 23 course . Some patient may also undergo radiotherapy stem cell transplantation .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>6-Mercaptopurine</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Newly diagnose acute lymphoblastic leukemia meeting 1 follow risk definition : Standardrisk disease : Age 1 9 year White blood cell ( WBC ) &lt; 50/mm^3 OR ( 12 ; 21 ) molecular fusion product positive disease Good response prior prednisone ( day 8 peripheral blood blast &lt; 1,000/mm^3 ) None follow subtypes : Tcell ( 9 ; 22 ) ( 4 ; 11 ) ( 1 ; 19 ) Molecular Bone marrow ( BM ) M1 M2 day 15 , BM remission ( &lt; 5 % blast ) day 33 Intermediaterisk disease : Good response prior prednisone BM M1/M2 day 15 Meets 1 follow criterion : At least 10 year old WBC &gt; 50/mm^3 Under 1 year old without Mixed Lineage Leukemia ( MLL ) gene rearrangement Tcell OR ( 1 ; 19 ) molecular fusion product positive . Standardrisk patient BM M3 day 15 If minimal residual disease ( MRD ) available , day 33 MRD &lt; 10^2 Highrisk disease , meet 1 follow criterion : Poor response prior prednisone ( 9 ; 22 ) molecular fusion product ( BCR/ABL1 ) , ( 4 ; 11 ) molecular fusion product ( MLL/AF4 ) Intermediaterisk patient BM M3 day 15 BM M2/M3 day 33 If MRD available , flow cytometry/polymerase chain reaction ( PCR ) &gt; 10 % day 15 OR MRD &gt; 10^2 day 33 OR MRD ( miniM phase M phase ) &gt; 10^3 day 84 PATIENT CHARACTERISTICS : Not specify PRIOR CONCURRENT THERAPY : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>untreated childhood acute lymphoblastic leukemia</keyword>
	<keyword>childhood acute lymphoblastic leukemia remission</keyword>
	<keyword>B-cell childhood acute lymphoblastic leukemia</keyword>
	<keyword>T-cell childhood acute lymphoblastic leukemia</keyword>
</DOC>